Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism

Neuro-Oncology Practice

Volumn 3, Issue 2, 2016, Pages 87-96

  Khoury, Michael Nabil ^a,b   Missios, Symeon ^c   Edwin, Natasha ^d   Sakruti, Susmita ^e   Barnett, Gene ^d   Stevens, Glen ^d   Peereboom, David M ^d   Khorana, Alok A ^d   Ahluwalia, Manmeet S ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Louisiana State University Health Sciences Center at Shreveport   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anticoagulation; Glioblastoma; Intracranial hemorrhage; Search terms; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RAMUCIRUMAB; VASCULOTROPIN; WARFARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

EID: 84994620859     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npv028     Document Type: Article

References (24)

1. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106(4):601-608.
2. Khorana AA, Cancer and coagulation. Am J Hematol. 2012;87(Suppl 1):S82-S87.
3. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007; 9(2):89-95.
4. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13(3):334-336.
5. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-1596.
6. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010;8(2):221-227.
7. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol. 2006; 80(3):313-332.
8. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. 2009;29(10):4309-4313.
9. Kidwell CS, Wintermark M. Imaging of intracranial haemorrhage. Lancet Neurol. 2008;7(3):256-267.
10. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493-498.
11. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006;24(8):1310-1318.
12. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost. 2014;40(3):325-331.
13. Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453-461.
14. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320-328.
15. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10(3):355-360.
16. Khaldi A, Helo N, Schneck MJ, Origitano TC. Venous thromboembolism:deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011;114(1):40-46.
17. Lazio BE, Simard, Anticoagulation in neurosurgical patients. Neurosurgery. 1999;45(4):838-847; discussion 847-838.
18. Begg RK, Tirosh O, Said CM, et al. Gait training with real-time augmented toe-ground clearance information decreases tripping risk in older adults and a person with chronic stroke. Front Hum Neurosci. 2014;8:243.
19. Yogev-Seligmann G, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord. 2008;23(3):329-342; quiz 472.
20. Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J AmGeriatr Soc. 2012;60(11):2127-2136.
21. Segev-Jacubovski O, Herman T, Yogev-Seligmann G, Mirelman A, Giladi N, Hausdorff JM. The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk? Expert Rev Neurother. 2011;11(7):1057-1075.
22. Zwimpfer TJ, Brown J, Sullivan I, Moulton RJ. Head injuries due to falls caused by seizures: a group at high risk for traumatic intracranial hematomas. J Neurosurg. 1997;86(3):433-437.
23. Levin VA. Cancer in the Nervous System. 2nd ed. New York, NY: Oxford University Press; 2002.
24. Prayson RA. Neuropathology. 2nd ed. Philadelphia, PA: Saunders; 2012.